|
顯示項目 771446-771455 / 2348674 (共234868頁)
<< < 77140 77141 77142 77143 77144 77145 77146 77147 77148 77149 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2014 |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
|
Chen, Mei-Ling; Yan, Bo-Shiun; Lu, Wan-Chih; Chen, Mei-Huei; Yu, Sung-Liang; Yang, Pan-Chyr Cheng, Ann-Lii; 俞松良; 楊泮池; 陳美齡; 鄭安理; 顏伯勳 |
| 臺大學術典藏 |
2018-09-10T14:50:19Z |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
|
Chen, M.-L. and Yan, B.-S. and Lu, W.-C. and Chen, M.-H. and Yu, S.-L. and Yang, P.-C. and Cheng, A.-L.; Chen, Mei-Ling;Yan, Bo-Shiun;Lu, Wan-Chih;Chen, Mei-Huei;Yu, Sung-Liang;Yang, Pan-Chyr
Cheng, Ann-Lii; 俞松良;楊泮池;陳美齡;鄭安理;顏伯勳; 俞松良;楊泮池;陳美齡;鄭安理;顏伯勳; Hsu, F.M.; SUNG-LIANG YU; Chen, Mei-Ling; Chen, Mei-Ling; Yan, Bo-Shiun; BO-SHIUN YAN; Hsu, F.M.; ANN-LII CHENG; Lu, Wan-Chih; Chen, Mei-Huei; Chen, Mei-Huei; Yu, Sung-Liang; Yang, Pan-Chyr
Cheng, Ann-Lii; 楊泮池 |
| 臺大學術典藏 |
2020-01-21T01:20:42Z |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
|
Cheng A.-L.; Yang P.-C.; Yu S.-L.; Chen M.-H.; Lu W.-C.; BO-SHIUN YAN; Chen M.-L. |
| 臺大學術典藏 |
2020-12-02T02:33:42Z |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
|
Chen M.-L.;Yan B.-S.;Lu W.-C.;Chen M.-H.;Yu S.-L.;PAN-CHYR YANG;Cheng A.-L.; Chen M.-L.; Yan B.-S.; Lu W.-C.; Chen M.-H.; Yu S.-L.; PAN-CHYR YANG; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:42:24Z |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
|
Chen M.-L.; Yan B.-S.; Lu W.-C.; Chen M.-H.; Yu S.-L.; Yang P.-C.; ANN-LII CHENG |
| 國立成功大學 |
2022-11 |
Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8(+) T cell activation to eradicate hepatocellular carcinoma
|
Cheng;-Chia, Chun;Ho;Ai-Sheng;Peng;Cheng-Liang;Chang;Jungshan;Sie;Zong-Lin;Wang;Chih-Liang;Chen;Yi-Li;Chen;Cheng-Yi |
| 國立成功大學 |
2022 |
Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma
|
Cheng, Cheng C.-C.;Ho, A.-S.;Peng, C.-L.;Chang, J.;Sie, Z.-L.;Wang, C.-L.;Chen, Y.-L.;Chen, Chen C.-Y. |
| 中山醫學大學 |
2019-11 |
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status
|
Lee, Shou-Wu;Lee, Teng-Yu;Peng, Yen-Chun;Yang, Sheng-Shun;Yeh, Hong-Zen;Chang, Chi-Sen |
| 亞洲大學 |
2019-07 |
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
|
郭集慶;Kok, Victor C.;陳玉菁;CHEN, YU-CHING;陳洋源;Chen, Yang-Yuan;蘇裕傑;Su, Yu-Chieh;古明昌;Ku, Ming-Chang;郭榮宗;Kuo, Jung-Tsung;吉田剛;Yoshida, Go J. |
| 國立成功大學 |
2009-11-27 |
Sorafenib 抑制Erk/Pin-1訊息傳導路徑降低 Myeloid cell leukemia-1表現促使乳癌化療敏感性
|
Ding, Qingqing;Huo, Longfei;Yang, Jer-Yen;Xia, Weiya;魏永昆;Liao, Yong;張君如;李東芳;顏家瑞;Cheng, Rita Yun-Ju;許榮茂;郭旭萍;洪明奇 |
顯示項目 771446-771455 / 2348674 (共234868頁)
<< < 77140 77141 77142 77143 77144 77145 77146 77147 77148 77149 > >>
每頁顯示[10|25|50]項目
|
